At the time of writing, AbCellera Biologics Inc [ABCL] stock is trading at $4.52, up 3.43%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ABCL shares have gain 31.78% over the last week, with a monthly amount glided 19.89%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
AbCellera Biologics Inc [NASDAQ: ABCL] stock has seen the most recent analyst activity on November 07, 2025, when Leerink Partners downgraded its rating to a Market Perform but kept the price target unchanged to $4 for it. On August 20, 2024, downgrade downgraded it’s rating to Hold. The Benchmark Company upgraded its rating to a Buy but stick to its price target of $9 on February 22, 2024. KeyBanc Capital Markets initiated its recommendation with an Overweight and recommended $6 as its price target on December 05, 2023. The Benchmark Company downgraded its rating to Hold for this stock on November 06, 2023.
For the past year, the stock price of AbCellera Biologics Inc fluctuated between $1.89 and $6.51. Currently, Wall Street analysts expect the stock to reach $20.17 within the next 12 months. AbCellera Biologics Inc [NASDAQ: ABCL] shares were valued at $4.52 at the most recent close of the market. An investor can expect a potential return of 346.24% based on the average ABCL price forecast.
Analyzing the ABCL fundamentals
According to AbCellera Biologics Inc [NASDAQ:ABCL], the company’s sales were 35.32M for trailing twelve months, which represents an 37.62% jump. Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at -7.4%, Pretax Profit Margin comes in at -5.14%, and Net Profit Margin reading is -4.86%. To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is -0.17 and Total Capital is -0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that AbCellera Biologics Inc [NASDAQ:ABCL] has a current ratio of 10.10. Further, the Quick Ratio stands at 10.10, while the Cash Ratio is 1.57. Considering the valuation of this stock, the price to sales ratio is 38.31, the price to book ratio is 1.40.
